Immunity After COVID-19 Vaccination

Status unconfirmed

Conditions studied: Immunity to COVID-19

In brief

The purpose of the research is to evaluate new blood tests, which measure immunity to the COVID-19 coronavirus after vaccination. These tests will be used to measure T-cell and antibody immunity after COVID-19 vaccination. Recent studies show that less than one-fifth of chronically immunosuppressed transplant recipients developed anti-receptor-binding domain antibodies after the first dose of the Pfizer vaccine (Boyarski, 2021). ood sampling at periodic intervals. These samples will be used to measure T-cell and antibody immunity to the COVID-19 coronavirus.

Key facts

Study ID

NCT04883164

Run by

Plexision

People needed

300

Starts

2021-04-27

Expected to finish

2023-03-31

Last updated by the study team

2021-05-12

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• IRB-approved informed consent,
• age 18 years or older, male or female,
• anyone considering COVID-19 vaccination or anyone that has received COVID-19 vaccination.
• Subjects can enroll at anytime after vaccination even though they may not have enrolled before vaccination.
• For individuals previously tested at Plexision for other purposes, and who have since been vaccinated, residual cells stored for quality control and potential repeat testing will be used to establish earlier measurement of cellular and antibody immunity as described in Table 1.

You may not qualify if…

• Failure to provide informed consent

Where it is running

• Plexision — Pittsburgh, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.